Facebook: Analysts Expect $3.03 In Q2 Earnings Per Share

Facebook (NASDAQ: FB) will be reporting its second quarter financial results today after the markets close. Analysts have a consensus $391.39 12-month price target on the company, via a total of 55 analysts, with 19 analysts having strong buy ratings. 27 analysts meanwhile have buy ratings, 7 have hold ratings, and two analysts have sell ratings on the company. The street high comes from Credit Suisse with a $480 price target, and the lowest target sits at $225 from Societe Generale.

38 analysts have revenue estimates for the second quarter. The mean revenue estimate between all 38 analysts is $27.87 billion; this number has been revised upwards from $24.28 billion at the start of the year. The highest revenue estimate is $28.75 billion, while the lowest is $27 billion.

Onto EBITDA estimates, there are currently 25 analysts who have second-quarter EBITDA estimates. The mean is currently $14.48 billion, with this number having been revised upwards from $11.78 billion at the start of the year. The street high estimate currently sits at $15.59 billion in EBITDA and the lowest is $12.36 billion.

Analysts estimate that quarterly earnings per share will come in at $3.03, with this number being revised upwards from $2.31 at the start of the year. Street high is $3.41 and the lowest estimate is $2.36 per share for the quarter.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Agnico Q1 Earnings Results Overshadowed By A Sinking Gold Price

Why More People Are Starting to Feel Broke | Darrell Thomas – VRIC Media

Newmont Q1 Earnings: A Billion In Free Cash Flow… A Month!

Recommended

Selkirk Copper Strikes New Lens Beneath Old Pit, Launches 50,000 Metre Phase 2 Program

Silver47 Pulls High-Grade Gold and Silver Assays from Nevada Vein Network At Kennedy

Related News

Canopy Growth: BofA Raises Price Target On The Back Of MORE Act Vote

This morning BofA Securities raised their 12-month price target on Canopy Growth Corp (TSX: WEED)...

Monday, November 30, 2020, 02:17:00 PM

Curaleaf: Consensus Estimate Falls To $20.18 After Weak Guidance

On March 3rd, Curaleaf Holdings, Inc. (CSE: CURA) reported its fourth quarter and full year...

Friday, March 11, 2022, 04:20:00 PM

Stifel-GMP: Canopy Growth CEO’s Legacy is “Poor Execution, Misallocated Capital, and Mismanaged Expectations.”

Earlier this month, Canopy Growth Corp (TSX: WEED) (NASDAQ: CGC) reported their fiscal second-quarter 2022...

Sunday, November 21, 2021, 12:03:00 PM

WeCommerce: Canaccord Lowers Price Target Following Marketing Meetings

Over the last few weeks, Canaccord hosted a number of marketing meetings for WeCommerce (TSXV:...

Wednesday, February 2, 2022, 04:04:00 PM

Twitter Inc: The Mods Must Be Crazy

With about two weeks left in his term, two days after an angry MAGA mob...

Saturday, January 9, 2021, 05:00:00 PM